The labor union at Samsung Biologics has issued a formal warning regarding a potential strike, citing systemic governance failures. Representing approximately 75% of the company's workforce, the union's move poses a significant threat to operational stability and global manufacturing commitments. The dispute centers on allegations of severe lapses in ESG standards and corporate governance within the organization. Industry experts warn that a work stoppage could create structural risks across the global CDMO sector, where Samsung Biologics is a dominant player. This escalation follows a broader trend of labor unrest within the Samsung Group, now expanding to its critical biotechnology growth engine. Market sentiment remains cautious as the potential disruption could impact the company's stock performance and its standing with international partners.

स्रोत:businesswire.commk.co.krbiz.chosun.comlaw360.combigmoleculewatch.comlifesciencesipreview.comjdsupra.cominsights.citeline.comhoyngrokhmonegier.comgoodwinlaw.com